$30.27
2.29%
NYSE, Sep 18, 04:01 pm EDT. Closed.
ISIN
US02157Q1094
Symbol
ANRO

Alto Neuroscience Stock price

$30.27
-3.86 11.31% 1M
+7.75 34.41% 6M
+12.47 70.06% YTD
+26.16 636.50% 1Y
+14.27 89.19% 3Y
+14.27 89.19% 5Y
+14.27 89.19% 10Y
+14.27 89.19% 20Y
NYSE, Closing price Fri, Sep 18 2026
-0.71 2.29%
ISIN
US02157Q1094
Symbol
ANRO
Industry

Is Alto Neuroscience a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$962.8m
Net debt
positive
Cash
$243.7m
Shares outstanding
35.1m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.4
Financial Health
Equity Ratio
81.8%
Return on Equity
-
ROCE
-37.2%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-87.6m
EBIT
$-88.3m
Net Income
$-84.2m
Free Cash Flow
$-68.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-25.8%
EBIT
-25.7%
Net Income
-29.9%
Free Cash Flow
-21.6%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-2.0
FCF per Share
$-2.0
Short interest
11.5%
Employees
68
Rev per Employee
-

Alto Neuroscience Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Alto Neuroscience forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a Alto Neuroscience forecast:

Buy
88%
Hold
12%

Financial data from Alto Neuroscience

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
0% 0%
-
- Research and Development Expense 65 65
38% 38%
-
-88 -88
26% 26%
-
- Depreciation and Amortization 0.69 0.69
10% 10%
-
EBIT (Operating Income) EBIT -88 -88
26% 26%
-
Net Profit -84 -84
30% 30%
-

In millions USD.

Don't miss a Thing! We will send you all news about Alto Neuroscience directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alto Neuroscience Stock News

Neutral
Business Wire
23 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026. Mr. Smith will continue to lead Alto's finance function and oversee corporate s...
Neutral
Business Wire
about one month ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates. “The...
Neutral
Business Wire
2 months ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a pric...
More Alto Neuroscience News

Company Profile

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Los Altos, CA.

Head office United States
CEO Dr. Etkin
Employees 68
Founded 2019
Website www.altoneuroscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today